150 related articles for article (PubMed ID: 12500340)
1. Use of conventional antipsychotics and the cost of treating schizophrenia.
Lyu RR; McCombs JS; Johnstone BM; Muse DN
Health Care Financ Rev; 2001; 23(2):83-99. PubMed ID: 12500340
[TBL] [Abstract][Full Text] [Related]
2. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
McCombs JS; Luo M; Johnstone BM; Shi L
Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
[TBL] [Abstract][Full Text] [Related]
3. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
6. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
[TBL] [Abstract][Full Text] [Related]
7. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Yu AP; Atanasov P; Ben-Hamadi R; Birnbaum H; Stensland MD; Philips G
Value Health; 2009; 12(5):708-15. PubMed ID: 19508658
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
10. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.
Seabury SA; Goldman DP; Kalsekar I; Sheehan JJ; Laubmeier K; Lakdawalla DN
Am J Manag Care; 2014 Feb; 20(2):e52-60. PubMed ID: 24738555
[TBL] [Abstract][Full Text] [Related]
11. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
12. Need for therapeutic guidelines for antipsychotics under a prescription cap.
Sutherland LG
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S19-22. PubMed ID: 9872690
[No Abstract] [Full Text] [Related]
13. Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.
Abouzaid S; Tian H; Zhou H; Kahler KH; Harris M; Kim E
Community Ment Health J; 2014 Jan; 50(1):51-8. PubMed ID: 23229052
[TBL] [Abstract][Full Text] [Related]
14. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
Walthour A; Seymour L; Tackett R; Perri M
Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
[TBL] [Abstract][Full Text] [Related]
15. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts.
Martin BC; Miller LS; Kotzan JA
Schizophr Res; 2001 Mar; 47(2-3):281-92. PubMed ID: 11278146
[TBL] [Abstract][Full Text] [Related]
17. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
19. Use patterns for antipsychotic medications in medicaid patients with schizophrenia.
McCombs JS; Nichol MB; Stimmel GL; Shi J; Smith RR
J Clin Psychiatry; 1999; 60 Suppl 19():5-11; discussion 12-3. PubMed ID: 10507275
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.
Markowitz M; Karve S; Panish J; Candrilli SD; Alphs L
BMC Psychiatry; 2013 Oct; 13():246. PubMed ID: 24094241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
